Abstract
Neurofibrillary pathology contributes to neuronal dysfunction and correlates with the clinical progression of Alzheimer’s disease (AD). Tau phosphorylation is mainly regulated by a balance of glycogen synthase kinase-3β (GSK-3β) and protein phosphatase 2A (PP2A) activities. Cornel iridoid glycoside (CIG) is a main component extracted from Cornus officinalis. The purpose of this study was to investigate the effects of CIG on GSK-3β and PP2A, thus to explore the mechanisms of CIG to inhibit tau hyperphosphorylation. The rat model of tau hyperphosphorylation was established by intraventricular injection of wortmannin and GF-109203X (GFX) to activate GSK-3β. The results showed that intragastrical administration of CIG inhibited tau hyperphosphorylation in the brain of rats induced by wortmannin/GFX. The results in vivo and in vitro exhibited that CIG inhibited tau hyperphosphorylation and GSK-3β over-activation. In the mechanism of action, CIG’s attenuating GSK-3β activity was found to be dependent on PI3K/AKT signaling pathway. PP2A catalytic C subunit (PP2Ac) siRNA abrogated the effect of CIG on PI3K/AKT/GSK-3β. Additionally and crucially, we also found that CIG inhibited the demethylation of PP2Ac at Leu309 in vivo and in vitro. It enhanced PP2A activity, decreased tau hyperphosphorylation, and protected cell morphology in okadaic acid (OA)-induced cell model in vitro. PP2Ac siRNA abated the inhibitory effect of CIG on tau hyperphosphorylation. Moreover, CIG inhibited protein phosphatase methylesterase-1 (PME-1) and demethylation of PP2Ac, enhanced PP2A activity, and decreased tau hyperphosphorylation in PME-1-transfectd cells. Taken together, CIG inhibited GSK-3β activity via promoting P13K/AKT and PP2A signaling pathways. In addition, CIG also elevated PP2A activity via inhibiting PME-1-induced PP2Ac demethylation to inhibit GSK-3β activity, thus regulated the cross-talk between GSK-3β and PP2A signaling and consequently inhibited tau hyperphosphorylation. These results suggest that CIG may be a promising agent for AD therapy.
Highlights
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly
The results showed that intraventricular injection of wortmannin/GFX induced an increase in the expression of glycogen synthase kinase-3β (GSK-3β) and a decrease in phosphorylated GSK-3β at Ser9, led to an increase in tau hyperphosphorylation in the hippocampus and memory impairment in rats
We examined whether Cornel iridoid glycoside (CIG) affected GSK-3β activity when phosphatase 2A (PP2A) was inhibited by PP2A catalytic C subunit (PP2Ac) Small Interfering RNA (siRNA)
Summary
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly. The presence of neurofibrillary tangles (NFTs) in neurons is one of the main characteristic pathological events in AD. Data strongly suggest that neurofibrillary pathology contributes to neuronal dysfunction and correlates with the clinical progression of AD (Holtzman et al, 2011; Murray et al, 2015). NFTs are composed of abnormally hyperphosphorylated tau protein. Tau phosphorylation is regulated by several kinases and phosphatases (Lee et al, 2001; Hardy, 2006). Novel strategies have aimed at targeting tau hyperphosphorylation in neurodegenerative disease, suggesting that kinase inhibitors or phosphatase activators will be a potential therapy target (Hanger et al, 2009; Clavaguera et al, 2014)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.